Company / Inventory
Jazz Pharmaceuticals Inventory History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$417.0M
FY2025
5-year range
$417.0M / $1.1B
FY2021-FY2025
Trend
-13.2%
vs FY2024
Sector context
#24 of 105
Health Care
What the data says
Jazz Pharmaceuticals's inventory of $417M is higher than 77% of companies in the Health Care sector (FY2025). Inventory has declined for 4 consecutive years, from $1.1B in FY2021 to $417M in FY2025.
Based on SEC 10-K filings.
$417M in FY2025 with a 5-year CAGR of +34.3%. Top quartile in the Health Care sector.
Declined from $597M to $417M over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- +34.3%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 105This company $417.0M Sector average $885.3M
▼
-52.9% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's inventory has declined for 4 consecutive years.
- 5-year CAGR of +34.3%, indicating consistent growth.
- In FY2025, inventory decreased 13.2% year-over-year.
- Ranks #24 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $417.0M | -13.2% |
| FY2024 | $480.4M | -19.5% |
| FY2023 | $597.0M | -16.4% |
| FY2022 | $714.1M | -33.4% |
| FY2021 | $1.1B | +1024.5% |
| FY2020 | $95.4M | +21.4% |
| FY2019 | $78.6M | +48.4% |
| FY2018 | $53.0M | +22.5% |
| FY2017 | $43.2M | +27.0% |
| FY2016 | $34.1M | +75.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026